386 related articles for article (PubMed ID: 22644798)
1. Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro.
Kamen BA; Smith AK
Cancer Chemother Pharmacol; 2012 Jul; 70(1):113-20. PubMed ID: 22644798
[TBL] [Abstract][Full Text] [Related]
2. Determinants of the activities of antifolates delivered into cells by folate-receptor-mediated endocytosis.
Zhao R; Visentin M; Goldman ID
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1163-73. PubMed ID: 25847479
[TBL] [Abstract][Full Text] [Related]
3. A new 18F-labeled folic acid derivative with improved properties for the PET imaging of folate receptor-positive tumors.
Ross TL; Honer M; Müller C; Groehn V; Schibli R; Ametamey SM
J Nucl Med; 2010 Nov; 51(11):1756-62. PubMed ID: 20956469
[TBL] [Abstract][Full Text] [Related]
4. Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging.
Hekman MCH; Boerman OC; Bos DL; Massuger LFAG; Weil S; Grasso L; Rybinski KA; Oosterwijk E; Mulders PFA; Rijpkema M
Mol Pharm; 2017 Oct; 14(10):3457-3463. PubMed ID: 28826214
[TBL] [Abstract][Full Text] [Related]
5. Folic acid mediates activation of the pro-oncogene STAT3 via the Folate Receptor alpha.
Hansen MF; Greibe E; Skovbjerg S; Rohde S; Kristensen AC; Jensen TR; Stentoft C; Kjær KH; Kronborg CS; Martensen PM
Cell Signal; 2015 Jul; 27(7):1356-68. PubMed ID: 25841994
[TBL] [Abstract][Full Text] [Related]
6. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis.
Zhao R; Zhang S; Hanscom M; Chattopadhyay S; Goldman ID
Clin Cancer Res; 2005 Feb; 11(3):1294-301. PubMed ID: 15709201
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.
Golani LK; Islam F; O'Connor C; Dekhne AS; Hou Z; Matherly LH; Gangjee A
Bioorg Med Chem; 2020 Jun; 28(12):115544. PubMed ID: 32503687
[TBL] [Abstract][Full Text] [Related]
8. Farletuzumab in lung cancer.
Thomas A; Maltzman J; Hassan R
Lung Cancer; 2013 Apr; 80(1):15-8. PubMed ID: 23357463
[TBL] [Abstract][Full Text] [Related]
9. Folate transporter dynamics and therapy with classic and tumor-targeted antifolates.
O'Connor C; Wallace-Povirk A; Ning C; Frühauf J; Tong N; Gangjee A; Matherly LH; Hou Z
Sci Rep; 2021 Mar; 11(1):6389. PubMed ID: 33737637
[TBL] [Abstract][Full Text] [Related]
10. Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer.
Walters CL; Arend RC; Armstrong DK; Naumann RW; Alvarez RD
Gynecol Oncol; 2013 Nov; 131(2):493-8. PubMed ID: 23863359
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.
Wen Y; Graybill WS; Previs RA; Hu W; Ivan C; Mangala LS; Zand B; Nick AM; Jennings NB; Dalton HJ; Sehgal V; Ram P; Lee JS; Vivas-Mejia PE; Coleman RL; Sood AK
Clin Cancer Res; 2015 Jan; 21(2):448-59. PubMed ID: 25416196
[TBL] [Abstract][Full Text] [Related]
12. Farletuzumab, a monoclonal antibody directed against folate receptor alpha, shows no evidence of teratogenicity in cynomolgus monkeys.
Moriyama T; Kakiuchi D; Grasso L; Hutto DL; Fernando D; Schweizer C
Reprod Toxicol; 2018 Aug; 79():89-95. PubMed ID: 29928988
[TBL] [Abstract][Full Text] [Related]
13. Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability.
Chattopadhyay S; Tamari R; Min SH; Zhao R; Tsai E; Goldman ID
Oncologist; 2007 Jul; 12(7):808-15. PubMed ID: 17673612
[TBL] [Abstract][Full Text] [Related]
14. Molecular, biochemical, and cellular pharmacology of pemetrexed.
Goldman ID; Zhao R
Semin Oncol; 2002 Dec; 29(6 Suppl 18):3-17. PubMed ID: 12571805
[TBL] [Abstract][Full Text] [Related]
15. The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs.
Theti DS; Jackman AL
Clin Cancer Res; 2004 Feb; 10(3):1080-9. PubMed ID: 14871988
[TBL] [Abstract][Full Text] [Related]
16. Role for cytosolic folate-binding proteins in the compartmentation of endogenous tetrahydrofolates and the 5-formyl tetrahydrofolate-mediated enhancement of 5-fluoro-2'-deoxyuridine antitumor activity in vitro.
Matherly LH; Czajkowski CA; Muench SP; Psiakis JT
Cancer Res; 1990 Jun; 50(11):3262-9. PubMed ID: 2139802
[TBL] [Abstract][Full Text] [Related]
17. A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro.
Kamen BA; Smith AK
Adv Drug Deliv Rev; 2004 Apr; 56(8):1085-97. PubMed ID: 15094208
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications.
Chattopadhyay S; Moran RG; Goldman ID
Mol Cancer Ther; 2007 Feb; 6(2):404-17. PubMed ID: 17308042
[TBL] [Abstract][Full Text] [Related]
19. Characterization of folate uptake by choroid plexus epithelial cells in a rat primary culture model.
Wollack JB; Makori B; Ahlawat S; Koneru R; Picinich SC; Smith A; Goldman ID; Qiu A; Cole PD; Glod J; Kamen B
J Neurochem; 2008 Mar; 104(6):1494-503. PubMed ID: 18086128
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed improves tumor selectivity of 111In-DTPA-folate in mice with folate receptor-positive ovarian cancer.
Müller C; Schibli R; Krenning EP; de Jong M
J Nucl Med; 2008 Apr; 49(4):623-9. PubMed ID: 18344429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
